1. Clinical significance of BRAF/NRAS concurrent mutations in a clinic‐based metastatic melanoma cohort. (1st May 2020) Authors: del Regno, L.; Louveau, B.; Battistella, M.; Sadoux, A.; Baroudjian, B.; Delyon, J.; Serror, K.; Allayous, C.; Lebbe, C.; Mourah, S.; Jouenne, F. Journal: British journal of dermatology Issue: Volume 182:Number 5(2020) Page Start: 1281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical significance of BRAF/NRAS concurrent mutations in a clinic‐based metastatic melanoma cohort. (2nd December 2019) Authors: del Regno, L.; Louveau, B.; Battistella, M.; Sadoux, A.; Baroudjian, B.; Delyon, J.; Serror, K.; Allayous, C.; Lebbe, C.; Mourah, S.; Jouenne, F. Journal: British journal of dermatology Issue: Volume 182:Number 5(2020) Page Start: 1281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. (December 2018) Authors: Kandel, M.; Allayous, C.; Dalle, S.; Mortier, L.; Dalac, S.; Dutriaux, C.; Leccia, M.T.; Guillot, B.; Saiag, P.; Lacour, J.P.; Legoupil, D.; Lesimple, T.; Aubin, F.; Beylot-Barry, M.; Brunet-Possenti, F.; Arnault, J.P.; Granel-Brocard, F.; Stoebner, P.E.; Dupuy, A.; Maubec, E. Journal: European journal of cancer Issue: Volume 105(2018) Page Start: 33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗